关注
Peter Hartog
Peter Hartog
在 astrazeneca.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors
HJ Sijben, WM van Oostveen, PBR Hartog, L Stucchi, A Rossignoli, ...
Scientific Reports 11 (1), 12290, 2021
82021
Proteochemometric modeling identifies chemically diverse norepinephrine transporter inhibitors
BJ Bongers, HJ Sijben, PBR Hartog, A Tarnovskiy, AP IJzerman, ...
Journal of Chemical Information and Modeling 63 (6), 1745-1755, 2023
52023
The openOCHEM consensus model is the best-performing open-source predictive model in the First EUOS/SLAS joint compound solubility challenge
A Hunklinger, P Hartog, M Šícho, G Godin, IV Tetko
SLAS Discovery 29 (2), 100144, 2024
32024
Using test-time augmentation to investigate explainable AI: inconsistencies between method, model and human intuition
PBR Hartog, F Krüger, S Genheden, IV Tetko
Journal of Cheminformatics 16 (1), 39, 2024
22024
openOCHEM consensus model wins Kaggle First EUOS/SLAS Joint Compound Solubility Challenge
A Kopp, P Hartog, M Šícho, G Godin, I Tetko
2023
Label-free high-throughput screening assay for the identification of norepinephrine transporter inhibitors
HJ Sijben, WM van Oostveen, PBR Hartog, L Stucchi, A Rossignoli, ...
Sensing transport: label-free in itro assa s as an atTRACTi e alternati e …, 2022
2022
Brandon J. Bongers Abstract
BJ Bongers, P Hartog, HJ Sijben, LH Heitman, AP IJzerman, ...
系统目前无法执行此操作,请稍后再试。
文章 1–7